Association of serum Klotho and fibroblast growth factor-23 levels with vascular calcification severity in patients with chronic kidney disease: an observational cohort study
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04475-5 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Pei-Shan Peng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Vascular Calcification, Fibroblast Growth Factors, Glucuronidase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Western Medicine Guidance Project of Shanghai Science and Technology Commission.
Abstract (Originalsprache)
PURPOSE: In patients with chronic kidney disease (CKD), vascular calcification (VC) is common and influences patient's outcome and prognosis. However, evaluation methods for VC severity are limited. Klotho and fibroblast growth factor-23 (FGF-23) are biomarkers associating with VC development. This study aimed to explore the association of serum Klotho and FGF-23 levels with VC severity in patients with non-dialysis CKD. METHODS: Patients with non-dialysis CKD were enrolled during hospitalization and were divided into the following four groups on the basis of their coronary artery calcification (CAC) scores: non-VC (CAC scores = 0), mild VC (0 400). Serum Klotho and FGF-23 levels among the different groups were compared. RESULTS: A total of 154 non-dialysis CKD patients were enrolled. Correlation analysis showed that serum FGF-23 level (rho = 0.185, p = 0.022) was positively correlated with VC severity, whereas serum Klotho level (rho = - 0.196, p = 0.015) was negatively correlated with VC severity in patients with CKD. Multivariable regression analysis showed that Klotho level [odd ratio (OR) = 0.998, 95% confidence interval (CI) 0.996-0.999, p = 0.001] served as a protective factor for VC severity in patients with CKD, whereas FGF-23 level (OR = 1.005, 95% CI 1.001-1.009, p = 0.020) was identified as risk factor for VC severity. CONCLUSION: Serum Klotho and FGF-23 levels are potential predictors of VC severity in patients with non-dialysis CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China.
- Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China. luwei03@xinhuamed.com.cn.
Förderung
- The Western Medicine Guidance Project of Shanghai Science and Technology Commission
Zitieren
APA
Peng, P. S., & Lu, W. (2025). Association of serum Klotho and fibroblast growth factor-23 levels with vascular calcification severity in patients with chronic kidney disease: an observational cohort study. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04475-5
Vancouver
Peng PS, Lu W. Association of serum Klotho and fibroblast growth factor-23 levels with vascular calcification severity in patients with chronic kidney disease: an observational cohort study. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04475-5
BibTeX
@article{Peng2025,
author = {Peng, Pei-Shan and Lu, Wei},
title = {Association of serum Klotho and fibroblast growth factor-23 levels with vascular calcification severity in patients with chronic kidney disease: an observational cohort study},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04475-5}
}
EUVIMED